Outlook Therapeutics^® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agencyissued a positive opinion concerning the authorization of ONS-5010/LYTENAVA™, an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD).